Sen Chuck Grassley (R, Iowa), the ranking member of the Senate Finance Committee, is urging the National Institutes of Health (NIH) to incorporate stringent rules against ghostwriting in medical literature into its forthcoming updated disclosure guidelines.
Grassley's recommendation came with the June 24 release of a committee minority staff report that found that the role of pharmaceutical companies in medical publications remains veiled or undisclosed (http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf). The report also said the strengthening of journal authorship policies appears to have had only a small effect on ghostwriting and disclosure of industry financing of medical articles (such as hiring a third party to develop articles that cast a company's products in a positive light).
Mitka M. Grassley Boos Ghostwriting. JAMA. 2010;304(6):628. doi:10.1001/jama.2010.1077